BR112012011689A2 - process for the production of dabigatran etexilate - Google Patents

process for the production of dabigatran etexilate

Info

Publication number
BR112012011689A2
BR112012011689A2 BR112012011689A BR112012011689A BR112012011689A2 BR 112012011689 A2 BR112012011689 A2 BR 112012011689A2 BR 112012011689 A BR112012011689 A BR 112012011689A BR 112012011689 A BR112012011689 A BR 112012011689A BR 112012011689 A2 BR112012011689 A2 BR 112012011689A2
Authority
BR
Brazil
Prior art keywords
production
dabigatran etexilate
dabigatran
etexilate
formula
Prior art date
Application number
BR112012011689A
Other languages
Portuguese (pt)
Other versions
BR112012011689B1 (en
BR112012011689B8 (en
Inventor
Frieder Gnad
Helmut Heitger
Hermann Mueller-Boetticher
Ingo Heddesheimer
Rolf Dach
Siegfried Meineck
Stefan Schmitt
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41683288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012011689(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112012011689A2 publication Critical patent/BR112012011689A2/en
Publication of BR112012011689B1 publication Critical patent/BR112012011689B1/en
Publication of BR112012011689B8 publication Critical patent/BR112012011689B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

processo para a produção de etexilato de dabigatran. a presente invenção refere-se a um processo aperfeiçoado para a produção de etexilato de dabigatran, bem como compostos análogos da fórmula (7).process for the production of dabigatran etexilate. The present invention relates to an improved process for the production of dabigatran etexylate as well as analogous compounds of formula (7).

BR112012011689A 2009-11-18 2010-11-06 process for the production of dabigatran etexilate and intermediate compounds BR112012011689B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09176369 2009-11-18
EP09176369.8 2009-11-18
PCT/EP2010/066959 WO2011061080A1 (en) 2009-11-18 2010-11-06 Method for producing dabigatran etexilate

Publications (3)

Publication Number Publication Date
BR112012011689A2 true BR112012011689A2 (en) 2015-10-13
BR112012011689B1 BR112012011689B1 (en) 2021-05-04
BR112012011689B8 BR112012011689B8 (en) 2021-05-25

Family

ID=41683288

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011689A BR112012011689B8 (en) 2009-11-18 2010-11-06 process for the production of dabigatran etexilate and intermediate compounds

Country Status (19)

Country Link
US (2) US8399678B2 (en)
EP (1) EP2501692B1 (en)
JP (1) JP5746707B2 (en)
KR (1) KR101802132B1 (en)
CN (1) CN102612517B (en)
AR (1) AR079055A1 (en)
AU (1) AU2010321098B2 (en)
BR (1) BR112012011689B8 (en)
CA (1) CA2780715C (en)
CL (1) CL2012001171A1 (en)
DK (1) DK2501692T3 (en)
EA (1) EA023117B1 (en)
ES (1) ES2525112T3 (en)
IL (1) IL219247A (en)
MX (1) MX2012005358A (en)
NZ (1) NZ599587A (en)
PL (1) PL2501692T3 (en)
TW (1) TWI478912B (en)
WO (1) WO2011061080A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CN101980697A (en) * 2008-03-28 2011-02-23 贝林格尔.英格海姆国际有限公司 Process for preparing orally administered dabigatran formulations
BRPI0914788B1 (en) * 2008-06-16 2020-04-07 Boehringer Ingelheim Int process for producing an intermediate product of dabigatran etexylate
NZ589746A (en) 2008-07-14 2012-10-26 Boehringer Ingelheim Int Method for manufacturing medicinal compounds containing dabigatran
CN102209544A (en) 2008-11-11 2011-10-05 贝林格尔.英格海姆国际有限公司 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
US8399678B2 (en) 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate
JP2013511541A (en) 2009-11-18 2013-04-04 プレキシコン インコーポレーテッド Compounds and methods for kinase regulation and indications thereof
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
EP2522662A1 (en) * 2011-05-11 2012-11-14 Medichem, S.A. Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers
WO2013150545A2 (en) 2012-04-02 2013-10-10 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
CN103420982B (en) * 2012-05-24 2015-07-08 天津药物研究院 Dabigatran derivative, and preparation method and application thereof
CN103420994B (en) * 2012-05-24 2016-04-06 天津药物研究院 As the dabigatran ester derivative and its production and use of prodrug
CN103420984B (en) * 2012-05-24 2015-07-08 天津药物研究院 Dabigatran derivative used as prodrug, and preparation method and application thereof
CN102850325B (en) * 2012-06-19 2014-03-26 上海现代制药海门有限公司 Preparation method of Dabigatran etexilate key intermediate
CN102850326B (en) * 2012-06-19 2014-04-09 上海现代制药股份有限公司 Dabigatran etexilate intermediate, and preparation method and application thereof
CN102850327B (en) * 2012-06-19 2014-07-16 上海现代制药股份有限公司 Intermediate for preparing Dabigatran etexilate, and preparation method and application thereof
US9399616B2 (en) * 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
CA2907839C (en) * 2013-03-25 2021-11-23 Usv Limited Synthesis of dabigatran
CN103224469A (en) * 2013-05-16 2013-07-31 上海应用技术学院 Pradaxa analogue with fluorine-containing group modified benzene ring as center and synthesis method thereof
CN103288744A (en) * 2013-06-04 2013-09-11 上海应用技术学院 Fluorine group-containing-modified dabigatran etexilate analogue and synthetic method thereof
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104418805B (en) * 2013-09-11 2017-02-22 浙江海正药业股份有限公司 Dabigatran etexilate intermediate as well as preparation method and application thereof
CN104003977B (en) * 2014-06-05 2016-04-13 雅本化学股份有限公司 The preparation method of N-(2-chloromethyl-1-methyl isophthalic acid H-benzoglyoxaline-5-acyl group)-N-(pyridine-2-base)-3-alanine ethyl ester
US10112901B2 (en) 2014-07-03 2018-10-30 Shanghai Institute Of Pharmaceutical Industry Method for preparing dabigatran etexilate intermediate, and intermediate compound
CN105461688B (en) * 2014-08-26 2017-12-29 上海医药工业研究院 Benzimidazole compound K synthetic method
CN105523999B (en) * 2014-10-21 2020-04-24 重庆医药工业研究院有限责任公司 Synthesis method of dabigatran etexilate intermediate
CN104447697B (en) * 2014-11-24 2016-08-24 蚌埠丰原医药科技发展有限公司 A kind of preparation method of dabigatran etexilate intermediate
CN104910047B (en) * 2015-05-11 2017-06-06 常州市阳光药业有限公司 The preparation method of dabigatran etexilate intermediate
CN104987323B (en) * 2015-07-10 2017-08-22 浙江美诺华药物化学有限公司 A kind of preparation method of dabigatran etcxilate
CN106554370A (en) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 Dabigatran derivant containing phosphate ester and its production and use
CN105348148B (en) * 2015-11-30 2017-12-26 山东新华制药股份有限公司 The method for preparing the oxalates of the impurity of dabigatran etexilate intermediate condensation product
CN105566296A (en) * 2015-12-16 2016-05-11 蚌埠丰原医药科技发展有限公司 Method for preparing dabigatran amidated impurities
CN105669651B (en) * 2016-03-07 2018-03-06 山东罗欣药业集团股份有限公司 A kind of preparation technology of dabigatran etexilate methanesulfonate
CN105732433A (en) * 2016-04-13 2016-07-06 山东新华制药股份有限公司 Refining method of Dabigatran etexilate intermediate condensation compound
CN105777622A (en) * 2016-04-13 2016-07-20 山东新华制药股份有限公司 Method for preparing impurities of dabigatran ester intermediate cyclocompound
CN106083822B (en) * 2016-08-17 2018-09-11 本溪经济开发区博美医药新技术开发有限公司 A kind of preparation method of dabigatran etexilate methanesulfonate intermediate
CN106928195B (en) * 2017-03-29 2019-04-19 福建省微生物研究所 A kind of synthetic method of Dabigatran etexilate key intermediate
CN108373466B (en) * 2018-04-16 2020-04-10 宏冠生物药业有限公司 Preparation method of dabigatran etexilate
CN108640903A (en) * 2018-04-16 2018-10-12 宏冠生物药业有限公司 A kind of preparation method of dabigatran etexilate intermediate
CN108997316A (en) * 2018-08-17 2018-12-14 四川青木制药有限公司 A kind of preparation process of dabigatran etcxilate
CN111606885A (en) * 2020-06-18 2020-09-01 安徽鼎旺医药有限公司 Dabigatran etexilate mesylate and preparation method thereof
CN114380797A (en) * 2021-12-27 2022-04-22 山东诚汇双达药业有限公司 Synthesis method of dabigatran etexilate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (en) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
WO1999041231A1 (en) 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
US6242466B1 (en) * 1998-07-23 2001-06-05 Boehringer Ingelheim Pharma Kg Substituted phenylamidines
DE19833105A1 (en) * 1998-07-23 2000-01-27 Boehringer Ingelheim Pharma New N-amidinophenyl-1-carboxymethyl-4-piperidinepropanamide derivatives useful as antithrombotic, antiaggregatory, antitumor, antimetastatic, antiinflammatory and anti-osteoporosis agents
EP1609784A1 (en) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Process for the preparation of 4-(benzimidazolylmethylamino)-benzamidines
JPWO2006070878A1 (en) * 2004-12-28 2008-06-12 アステラス製薬株式会社 Carboxylic acid derivative or salt thereof
DE102005061624A1 (en) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of salts of 4- (benzimidazolylmethylamino) -benzamidines
DE102005061623A1 (en) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of 4- (benzimidazolylmethylamino) -benzamidines and their salts
EP1956018A1 (en) 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Method of preparing a derivative of benzimidazole
EP2271317B1 (en) 2008-03-28 2017-04-19 Boehringer Ingelheim International GmbH Method for manufacturing acid pellets
CN101980697A (en) 2008-03-28 2011-02-23 贝林格尔.英格海姆国际有限公司 Process for preparing orally administered dabigatran formulations
BRPI0914788B1 (en) 2008-06-16 2020-04-07 Boehringer Ingelheim Int process for producing an intermediate product of dabigatran etexylate
EP2300431B1 (en) 2008-06-16 2016-01-06 Boehringer Ingelheim International GmbH Process for the manufacture of an intermediate in the synthesis of dabigatran
NZ589746A (en) 2008-07-14 2012-10-26 Boehringer Ingelheim Int Method for manufacturing medicinal compounds containing dabigatran
US8399678B2 (en) 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate

Also Published As

Publication number Publication date
KR20120099039A (en) 2012-09-06
NZ599587A (en) 2014-06-27
PL2501692T3 (en) 2015-03-31
IL219247A0 (en) 2012-06-28
EA023117B1 (en) 2016-04-29
US8993770B2 (en) 2015-03-31
CL2012001171A1 (en) 2012-08-10
EA201200741A1 (en) 2013-02-28
MX2012005358A (en) 2012-05-29
KR101802132B1 (en) 2017-11-28
BR112012011689B1 (en) 2021-05-04
AU2010321098B2 (en) 2016-06-09
TWI478912B (en) 2015-04-01
CA2780715C (en) 2017-09-12
EP2501692B1 (en) 2014-09-03
DK2501692T3 (en) 2014-12-08
US20110275824A1 (en) 2011-11-10
CA2780715A1 (en) 2011-05-26
JP2013511482A (en) 2013-04-04
CN102612517B (en) 2014-09-17
AU2010321098A1 (en) 2012-05-17
BR112012011689B8 (en) 2021-05-25
EP2501692A1 (en) 2012-09-26
JP5746707B2 (en) 2015-07-08
CN102612517A (en) 2012-07-25
US20130158270A1 (en) 2013-06-20
TW201129555A (en) 2011-09-01
IL219247A (en) 2014-11-30
WO2011061080A1 (en) 2011-05-26
AR079055A1 (en) 2011-12-21
US8399678B2 (en) 2013-03-19
ES2525112T3 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
BR112012011689A2 (en) process for the production of dabigatran etexilate
BR112012028395A2 (en) process for preparing dithyine tetracarboxy diimides
IN2012DN02751A (en)
BR112012015490A2 (en) sweeteners and process for their production
BR112012008020B8 (en) drilling machine.
CR20110047A (en) NANOPARTICULATED COPPER COMPOUNDS
CU20130101A7 (en) DERIVATIVES OF 1,4-OXAZIN-3-IL-PIRIDIN-2-IL-ACETAMIDE, ASSETS AS BACE-1 OR BACE-2 INHIBITORS
ECSP13012612A (en) DERIVATIVES OF QUINAZOLIN-4- (3H) -ONA USED AS INHIBITORS OF P13 CINASA
BR112014019909A8 (en) PROCESS FOR THE PRODUCTION OF COMPOUNDS USEFUL AS OREXIN-2 RECEPTOR ANTAGONISTS
BR112012011961A2 (en) process for producing 5-fluoro-1-alkyl-3-fluoralkyl-1h-pyrazol-4-carboxylic acid chlorides
UA111142C2 (en) FOR THE PREPARATION OF SUBSTITUTED 2-FLUORACRYLIC ACID DERIVATIVES
EA201500234A1 (en) METHOD OF OBTAINING BENZOXASINONES
CY1116974T1 (en) 5-HYDROXYPYRIMINO-4-CARBOXAMIDE PRODUCT
MX362689B (en) Method for producing 3,5-bis(fluoroalkyl)-pyrazol-4-carboxylic acid derivatives and 3,5-bis(fluoroalkyl)-pyrazoles.
EA201000379A1 (en) METHOD OF OBTAINING 2-SULFINYL-1H-BENZOIMIDAZOLES
BR112015029399A2 (en) single step production of a polypropylene composition
UY31577A1 (en) PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1- (2H) -ISOQUINOLINONES
EA201390336A1 (en) METHOD OF OBTAINING INTERMEDIATE CONNECTION FOR SYNTHESIS OF MEDICINES
NZ720106A (en) A process for the preparation of regadenoson
BR112012001477A2 (en) Process for producing aryl substituted pyrazols.
UY32524A (en) SIP MODULATORS AND METHOD FOR PRODUCING AND USING THEM
BR112012026157A2 (en) process for preparing dithyine tetracarboximides.
BR112013005689A2 (en) method for producing pyridazinone compounds and intermediate thereof
BR112012026411A2 (en) process for preparing dithycin tetracarboxy diimines
BR112012008017A2 (en) 1,2,4-triazine, use of a 1,2,4-triazine and process for preparing a 1,2,4-triazine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 401/12 , C07C 257/20

Ipc: C07D 401/12 (2006.01), C07C 257/20 (2006.01), A61P

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF